Aldeyra Therapeutics Inc (ALDX)
5.345
+0.12
(+2.20%)
USD |
NASDAQ |
Oct 04, 16:00
5.50
+0.16
(+2.90%)
After-Hours: 20:00
Aldeyra Therapeutics Research and Development Expense (Annual): 29.46M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 29.46M |
| December 31, 2022 | 47.31M |
| December 31, 2021 | 44.94M |
| December 31, 2020 | 24.68M |
| December 31, 2019 | 44.35M |
| December 31, 2018 | 29.82M |
| December 31, 2017 | 16.30M |
| Date | Value |
|---|---|
| December 31, 2016 | 13.18M |
| December 31, 2015 | 7.574M |
| December 31, 2014 | 3.708M |
| December 31, 2013 | 1.542M |
| December 31, 2012 | 0.4693M |
| December 31, 2011 | 1.365M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
24.68M
Minimum
2020
47.31M
Maximum
2022
38.15M
Average
44.35M
Median
2019
Research and Development Expense (Annual) Benchmarks
| AbbVie Inc | 7.675B |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.31M |